LaFond said the drop request dropped late last year after she aired the concern during a television interview. But elsewhere, interest in ivermectin is high, although there is insufficient evidence that it can be used to treat COVID-19. And the sometimes dangerous effects when people use animal versions. The Food and Drug Administration said at least three people were hospitalized in February after being considered by a veterinarian. Warn that high doses can cause allergic reactions, seizures, liver injury, and even death.
Some experts say that some people stop using animal drugs because they are more readily available than drugs designed for humans. The formula is approved for tropical diseases and requires a prescription, and although ivermectin has been touted on social media as something that can be discontinued. The outbreak has not been cleared for use with COVID-19, a disease caused by the novel coronavirus.
“It’s like hydroxychloroquine,” said virologist Angela Rasmussen at Georgetown University’s Center for Global Health and Safety Science, referring to the malaria drugs that President Donald Trump used for. Trump pushed forward, which has proven to be ineffective against COVID-19. “It would be nice if ivermectin was effective – it had been used for years and was cheap. But from my knowledge, there is no information to suggest that it is good for COVID-19. ”
Ivermectin is highly effective in treating destructive parasitic infections such as river blindness and is safe when used in recommended doses.In 1970, Japanese and US scientists discovered the compound that led to its development and in 2015. Receive the Nobel Prize But compared to COVID-19, “no meaningful evidence” of efficacy, according to Merck, is a brand-name model. And the nation’s leading infectious disease physician organization recommends refraining from ivermectin outside clinical trials.
But Pierre Cory, a critical care physician, is unobstructed. Kory, co-founder of the Front Line Covid-19 Critical Care Alliance, a multinational group of doctors and scientists, says studies from around the world show ivermectin to be a “miracle drug”. For COVID-19 and should be applied immediately. He is against waiting for data from large randomized clinical trials. To permit use Saying that too many people die from COVID-19.
The National Institutes of Health may now wade into controversy A randomized clinical trial is being planned to explore whether older, approved drugs can be reused to reduce COVID-19, according to three people speaking on condition of anonymity. As no plans have yet been announced, Ivermectin is considered a top candidate for the trial, although details have not yet been finalized. Other possibilities include the decades-old antidepressant fluvoxamine and famotidine, which is the generic name of Pepcid, outside scientists. The goal is to get results within a few months.
A British trial called Recovery has provided important information about the older drug, finding that hydroxychloroquine did not help COVID-19 patients who were hospitalized while stear. Yeroid Dexametasone May Save Lives But the United States has lagged behind in running such trials as a fragmented healthcare system and a lack of financial incentive for drug companies to continue research into old and cheap drugs.
Interest in ivermectin for COVID-19 rose last spring after a small Australian study found the drug suppressed the replication of the coronavirus in lab tests. But scientists have warned that it is impossible for humans to take high enough doses of the drug to produce antiviral activity.
The accelerated sales of veterinary versions have made it harder for animal owners to find ivermectin for their pets and livestock.Tractor Supply, a national farm products retailer, has temporarily stopped selling a form of animal drug to prevent its use. appropriate Since then, it has resumed its product sales – “carefully labeled,” the company said in a statement.
“Right now, we don’t have solid evidence about the drug during the American Medical Association sponsored webinar on COVID-19 therapy,” said Janet Woodcock, Acting FDA Commissioner. And then about ivermectin, but again, we have advice on a lot of these agents, and many of them haven’t been disclosed. ”
Patti Gilliano, a 56-year-old nurse who lives near Houston, thought ivermectin was a key tool in her recovery from COVID-19 last summer. After she was hospitalized, she said she was treated with antiviral medication. But until she got home and saw her doctor to prescribe ivermectin, she said brain fog, night sweats and digestive problems were gone.
However, the scientists warn that the anecdote does not prove that the treatment works because most people who get COVID-19 will eventually recover.
Kory from the Critical Care Alliance It said a group of doctors was formed at the start of the epidemic to exchange information about possible treatments and to advocate for early steroid use, which is now part of the standard of care. Critically ill This past fall began to focus on ivermectin, as multiple studies conducted by Southeast Asian and South American countries suggest it may be helpful in treating COVID-19.
In an emotional testimony before the Senate Homeland Security Committee in December, Kory hailed the drugs as “Potential global solutions” for the epidemic After his testimony attracted widespread attention, Kory said his employer – Aurora St. Luke Medical Center in Milwaukee, tried to impose new contract restrictions that he claimed would interfere with his free speech. He declined to accept the restrictions and left, the hospital declined to comment.
He previously worked in the University of Wisconsin-Madison Health System. But quit his job in May, he said, because his supervisor refused to comply with his advice for COVID-19 patients to receive steroid treatment. That was a month before the first major clinical trial – the British Recovery trial – demonstrated the value of anabolic steroids. dexamethasone The health system declined to comment.
Kory said he now works as a “locum tenens” physician, a part-time physician, and as president and chief medical officer of the Front Line Covid-19 Critical Care Alliance.
In August, a NIH panel issued guidelines for the recommended COVID-19 treatment for the use of ivermectin outside of clinical trials. But after Kory and his colleagues’ presentation in January, the committee took a neutral stance, saying there was “Insufficient data are available to recommend or against the use of ivermectin in the treatment of COVID-19,” said some studies show benefit and others do not, but most studies “do have data that are not available to ivermectin. Incomplete and important methodological limitations that make it difficult to exclude common causes of bias. “
Several weeks later, the American Society of Infectious Diseases, which includes doctors in infectious diseases, said most ivermectin studies were too small, were not properly randomized, or had other defects and said the drug should not be used outside. The trial.Adarsh Bhimraj, an infectious disease physician at the Cleveland Clinic and member of the Treatment Guidance Committee, pointed out what he described as a well-designed randomized, placebo-controlled trial in Colombia that found it. That the drug does not help patients with mild COVID-19, the study was published in the Journal of the American Medical Association in early March.
The haste in accepting unapproved treatments reflects a understandable desire to find a silver bullet for the virus threat, Bhimaraj said. While some progress has been made on COVID-19 therapy, no game changer has yet been made, such as penicillin’s ability to kill the streptococcal bacteria.
Amid the debate, some doctors are trying to lower the temperature.
In a blog post earlier this year, Paul Sax, an infectious disease physician at Brigham and Women’s Hospital in Boston, acknowledged the debate over ivermectin, with the echo of his fight against hydroxychloroquine prompting doctors, but he cautioned doctors. It is not to be assumed that “because we are metabolized by hydroxychloroquine, this means that all other, all recycled anti-parasitic drugs will also fail.”
He shows cautious optimism that the drug may be useful, largely thanks to a recent meta-analysis, a statistical analysis from several studies by the University of Liverpool. The information said, Saxe said, “It looked stronger than they did with hydroxychloroquine. But we are not yet up to the level
Alice Crites contributed to this report.